Education
About Us
Working with TipRanks
Follow Us
Design Therapeutics, Inc. (DSGN)
:DSGN
DSGN Stock Chart & Stats
$6.17
-$0.66(-11.15%)
At close: 4:00 PM EST
$6.17
-$0.66(-11.15%)
Day’s Range― - ―
52-Week Range$2.60 - $7.77
Previous CloseN/A
Volume97.34K
Average Volume (3M)217.79K
Market Cap
$351.37M
Enterprise Value-$22.71M
Total Cash (Recent Filing)$216.28M
Total Debt (Recent Filing)$1.10M
Price to Earnings (P/E)―
Beta1.40
Next Earnings
Nov 05, 2025EPS Estimate
-0.34Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.34
Shares Outstanding56,948,128
10 Day Avg. Volume261,982
30 Day Avg. Volume217,790
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap-0.06
Enterprise Value/Revenue-38.63
Enterprise Value/Gross Profit133.61
Enterprise Value/Ebitda0.31
Forecast
1Y Price Target
$5.00Price Target Upside-18.96% Downside
Rating ConsensusHold
Number of Analyst Covering2
Bulls Say, Bears Say
Bulls Say
Clinical TrialsDSGN has now added additional human PK data to their corporate deck that shows improved exposure over the prior formulation at similar doses and a PK profile that is consistent with what they have seen in NHPs with both intravenous and subcutaneous delivery, which bodes well for the new candidate.
Drug DevelopmentDSGN's new product candidate, DT-216P2, contains a novel proprietary excipient which has addressed previous safety and PK issues in animal models.
Financial OutlookDSGN reported $229.7M in cash and equivalents, expected to fund operating expenses into 2029.
Bears Say
Clinical Trial DelaysThe US clinical hold could add to the delays seen in the program.
Regulatory ChallengesA clinical hold notice was received from the FDA in response to the IND submission, citing nonclinical deficiencies.
Design Therapeutics News
DSGN FAQ
What was Design Therapeutics, Inc.’s price range in the past 12 months?
Design Therapeutics, Inc. lowest stock price was $2.60 and its highest was $7.77 in the past 12 months.
What is Design Therapeutics, Inc.’s market cap?
Design Therapeutics, Inc.’s market cap is $351.37M.
When is Design Therapeutics, Inc.’s upcoming earnings report date?
Design Therapeutics, Inc.’s upcoming earnings report date is Nov 05, 2025 which is in 18 days.
How were Design Therapeutics, Inc.’s earnings last quarter?
Design Therapeutics, Inc. released its earnings results on Aug 07, 2025. The company reported -$0.34 earnings per share for the quarter, missing the consensus estimate of -$0.33 by -$0.01.
Is Design Therapeutics, Inc. overvalued?
According to Wall Street analysts Design Therapeutics, Inc.’s price is currently Overvalued.
Does Design Therapeutics, Inc. pay dividends?
Design Therapeutics, Inc. does not currently pay dividends.
What is Design Therapeutics, Inc.’s EPS estimate?
Design Therapeutics, Inc.’s EPS estimate is -0.34.
How many shares outstanding does Design Therapeutics, Inc. have?
Design Therapeutics, Inc. has 56,948,128 shares outstanding.
What happened to Design Therapeutics, Inc.’s price movement after its last earnings report?
Design Therapeutics, Inc. reported an EPS of -$0.34 in its last earnings report, missing expectations of -$0.33. Following the earnings report the stock price went up 7.809%.
Which hedge fund is a major shareholder of Design Therapeutics, Inc.?
Currently, no hedge funds are holding shares in DSGN
Design Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$5.00 (-18.96% Downside)
$5.00 (-18.96% Downside)
Hedge Fund Trend
Increased
By 263.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $3.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.7%
Last 30 Days ▼ 4.8%
Last 30 Days ▼ 4.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
9.20%
12-Months-Change
Fundamentals
Return on Equity
-26.77%
Trailing 12-Months
Asset Growth
-17.32%
Trailing 12-Months
Company Description
Design Therapeutics, Inc.
Design Therapeutics (DSGN) is a biotechnology company focused on developing novel therapies for serious degenerative diseases caused by nucleotide repeat expansions. The company operates within the pharmaceutical and biotechnology sectors, leveraging its GeneTAC platform to design small-molecule treatments that target the underlying genetic causes of these diseases. Design Therapeutics aims to address unmet medical needs in conditions such as Friedreich ataxia and other similar genetic disorders.
DSGN Stock 12 Month Forecast
Average Price Target
$5.00
▼(-18.96% Downside)
Technical Analysis
Assembly Biosciences
―
Korro Bio
―
Annexon Biosciences
―
Aura Biosciences Inc
―
Lexeo Therapeutics, Inc.
―
Ownership Overview
18.53% Insiders
6.87% Mutual Funds
37.98% Other Institutional Investors
31.15% Public Companies and
Individual Investors